Who is sponsoring NCT07207980?

NCT07207980 is sponsored by Parc Sanitari Pere Virgili.

What drugs are being tested in NCT07207980?

Interventions in NCT07207980: CREDOenAP intervention.

What condition does NCT07207980 study?

NCT07207980 studies Type 2 Diabetes Mellitus (T2DM).

Is NCT07207980 still recruiting?

NCT07207980 is currently not yet recruiting. Last updated 6 October 2025.

Last reviewed 2025-10-06 · How we verify

NCT07207980: CREDOenAP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lifestyle Intervention for Type 2 Diabetes in Primary Care (CREDOenAP)

Not yet recruiting NA Last updated 6 October 2025

What this trial tests

NA trial testing CREDOenAP intervention in Type 2 Diabetes Mellitus (T2DM) in 120 participants. Not yet recruiting.

Timeline

11 January 2026

Primary endpoint
30 June 2027

11 January 2028

Quick facts

Lead sponsor	Parc Sanitari Pere Virgili
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	11 January 2026
Primary completion	30 June 2027
Estimated completion	11 January 2028
Sites	1 location across Spain

Drugs / interventions tested

CREDOenAP intervention

Conditions studied

Type 2 Diabetes Mellitus (T2DM) — all drugs for Type 2 Diabetes Mellitus (T2DM) →

Sponsor

Parc Sanitari Pere Virgili — full company profile →

Who can join

Adults 18 to 80, any sex, with Type 2 Diabetes Mellitus (T2DM). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical trial is to determine whether an intensive lifestyle intervention can achieve remission of type 2 diabetes mellitus (T2DM) in adult patients treated in primary care. The main questions the study seeks to answer are: * What proportion of participants achieve diabetes remission after 6 months of intervention? * How many participants maintain remission 12 months after completing the program (18 months total)? Participants will: * Follow a personalized dietary plan with carbohydrate restriction. * Engage in moderate, accessible physical activity. * Implement strategies to improve circadian rhythm regularity. * Receive psychological counseling and support.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes Mellitus (T2DM)

Currently open trials in the same condition.

NCT07533539 — Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration · Phase 1 · recruiting
NCT07366775 — A Telenursing Program to Support Diabetes Self-Management · NA · active not recruiting
NCT07398495 — Multimodal Training Effects in Middle-Aged and Older Adults With Diabetic Sarcopenia · NA · recruiting
NCT07465224 — A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus · Phase 2 · recruiting
NCT07442006 — Glycemic Variability of Combination Therapies in T2DM · Phase 4 · recruiting

Other Parc Sanitari Pere Virgili trials

Trials by the same sponsor.

NCT07408882 — Evaluation of an Integrated Home Care Model · NA · recruiting
NCT06836167 — +AGIL Barcelona: Integrated Care for Community-Dwelling Frail Older Adults · NA · recruiting
NCT04115215 — Pre-FRONTal Brain STability, Key for Action Against Disability in AGing · NA · unknown
NCT03578991 — Diabetes as an Accelerator of Cognitive Impairment and Alzheimer's Disease · NA · completed
NCT03991390 — Effectiveness of Balance Exercise Program for Stroke Patients With Pusher Syndrome · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07207980 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Parc Sanitari Pere Virgili
Last refreshed: 6 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07207980.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing